Results 61 to 70 of about 13,317 (169)
Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.
, 2019 Echinocandins (caspofungin, micafungin, anidulafungin), targeting β-1,3-glucan synthesis of the cell wall, represent one of the three currently available antifungal drug classes for the treatment of invasive fungal infections.
Glampedakis, E., Aruanno, M., Lamoth, F.
core +1 more source
Endobronchial Aspergillosis Presenting as an Isolated Airway Lesion in an Immunocompromised Patient
Respirology Case Reports, Volume 14, Issue 9, September 2026.Endobronchial Aspergillus infection should be considered in immunocompromised patients presenting with airway obstruction, even in the absence of parenchymal lung involvement. This case highlights the potential for rapid clinical deterioration and the diagnostic challenges in distinguishing endobronchial aspergillosis from more aggressive forms of ...
Mohsen Sadeghi +3 more
wiley +1 more source
Mechanistic Investigations of a Novel Lactam Antifungal Agent Against Candida albicans
APMIS, Volume 134, Issue 9, September 2026.ABSTRACT Candida albicans presents a major, yet underestimated challenge in clinical settings due to its increased resistance to treatment. This study intended to focus on the utility of a novel proprietary lactam molecule, a quorum sensing (QS) inhibitor, against C. albicans. We assessed isolate susceptibility to lactam treatment. In addition, RNA‐Seq
Hafsa Abduljalil +6 more
wiley +1 more source
Mycoses, Volume 69, Issue 9, September 2026.ABSTRACT Background Central nervous system (CNS) aspergillosis is a life‐threatening infection with mortality rates exceeding 50%, especially in immunocompromised patients. Significant challenges persist due to limited antifungal drug penetration into the CNS, emerging resistance, and diagnostic delays, despite advancements in therapy and diagnostics ...
Moustafa A. Mansour +5 more
wiley +1 more source
Pharmacotherapy of Candida Infections with Echinocandins
, 2009 The classic recommended antifungal agents for the treatment of invasive Candida infections were amphotericin B, a lipid formulation of amphotericin B and fluconazole in both neutropenic or nonneutropenic patients as either primary or alternative ...
Javier Pemán +3 more
core +1 more source
Mycoses, Volume 69, Issue 9, September 2026.ABSTRACT Background Opportunistic yeasts account for a substantial proportion of invasive fungal infections and are important agents of healthcare‐associated infections, especially in intensive care units (ICUs). Objectives To describe the clinical and epidemiological characteristics of hospitalized patients with positive cultures for medically ...
Yasmim Passos Lima +8 more
wiley +1 more source
Susceptibility of Pneumocystis to Echinocandins in Suspension and Biofilm Cultures
, 2011 The targeted inhibition of cyst but not trophic development by anidulafungin, caspofungin, and micafungin on Pneumocystis murina and Pneumocystis carinii in rodent models of Pneumocystis ...
Margaret S. Collins, Melanie T. Cushion
core +1 more source
Long‐Term Use of Rezafungin: A Case Report and Insights Into Real‐World Access
Transplant Infectious Disease, EarlyView.
Jian Mei Li +2 more
wiley +1 more source
Mycoses, Volume 69, Issue 9, September 2026.ABSTRACT Background Fluconazole tolerance is an emerging phenotype in Candida albicans bloodstream infections, but its relationship to multilocus sequence typing (MLST) lineages and virulence traits is unclear. Objectives To investigate the relationships among MLST genotypes, fluconazole tolerance, and virulence phenotypes in C.
Shang‐Yi Lin +5 more
wiley +1 more source
A Multifactorial Azole Response in Clinically Relevant Fusarium Species Complexes
Mycoses, Volume 69, Issue 9, September 2026.ABSTRACT Background Fusarium spp. are clinically relevant filamentous fungi with intrinsically low susceptibility to multiple antifungal agents, particularly azoles, and are included in the World Health Organization fungal priority pathogens list.
Patrícia Helena Grizante Barião +5 more
wiley +1 more source